Proteintech announced the acquisition of ChromoTek


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Proteintech announced the acquisition of ChromoTek
The merger will enable the two companies to take full advantage of growing industry opportunities and more effectively address industry challenges

Proteintech, the reference standard for antibodies, announced the acquisition of ChromoTek, a manufacturer of single domain camelid antibodies, also known as nanoantibodies.

ChromoTek is the industry leader in nanoantibodies, high-throughput recombinant reagents used in research activities leading to groundbreaking discoveries. The merger will enable the two companies to take full advantage of growing industry opportunities and more effectively address industry challenges in single cell analysis, super resolution imaging and multiplexing assays.

"Our specialized nanoantibody-based tools seamlessly integrate with Proteintech's comprehensive antibody portfolio that covers a large part of the proteome," says Dr Marion Jung, CEO of ChromoTek. "It is exciting to collaborate with a company that shares our values ​​in terms of reproducibility and quality for the benefit of research and beyond," he adds.

Proteintech CEO Dr Jason Li commented: "This new collaboration will generate considerable value for the market. The availability of manufacturing facilities on three different continents will allow us to better meet the needs of the research market and will have a profound impact on translational science and therapeutic applications ".

Founded in 2002, Proteintech is a leading manufacturer of antibodies, proteins and immunoassays. The company has the largest unique portfolio of self-made antibodies that cover two-thirds of the human proteome. With more than 70,000 publications and a proven specificity, Proteintech offers antibodies and immunoassays for all areas of research. Additionally, Proteintech produces cytokines, growth factors, and other human-expressed proteins that are bioactive and meet current GMP standards. 

ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid nanoantibodies. Unlike traditional antibodies, nanoantibodies consist of a single polypeptide chain and are the smallest known antibodies. The company has unique expertise in developing nanoantibodies with the desired affinity, specificity, and format for applications in biomedical research areas where other antibody formats do not work. As the market and product leader in high-throughput reagents, we are proud to contribute to groundbreaking research discoveries around the world. 

Tags : #Proteintech #LatestNewsonProteintech22ndOct #ChromoTek #LatestNewsonChromoTek22ndOct #LatestPharmaNews22ndOct #LatestPharmaAcquisitionNews22ndOct #DrMarionJung #DrJasonLi

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026